Dr Sonnad asked panelists about the participants on payer panels who determine the cost-effectiveness of pathways.
Dr Sonnad asked panelists about the participants on payer panels who determine the cost-effectiveness of pathways.
Dr Malin said WellPoint uses an internal team of oncologists and pharmacists who collaborate on pathway recommendations. They also utilize an external advisory group of oncologists from community practices and academic centers who review the organization's outcome summaries and evidence of proposed pathways.
“We also make our pathways available on the Web so anyone can download them and there’s an e-mail address as well on the pathways themselves when you download them — any provider can provide feedback to us about the pathways,” Dr Malin said. They will monitor this feedback to determine whether certain patients may not require a pathway.
Dr Yu said that there should be ongoing and regular reviews of pathway guidelines, if they’re not already established. These are useful to determine variations and changes in pathway regimens.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen